Stocks · News reference
Tempest Therapeutics shares soared 66.53% after hours Tuesday following an exclusive option agreement expanding its in vivo CAR-T pipeline.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-09-28 AccNo: 0001213900-26-104034 Size: 408 KB Item 1.01: Entry into a Material Definitive Agreement Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Up to 9,534,164 Shares of Common Stock This prospectus relates to the offer and resale from time to time by the selling stockholders named in this prospectus, referred to as the selling stockholders, of up to 9,534,164
HC Wainwright & Co. analyst Joseph Pantginis maintains Tempest Therapeutics (NASDAQ:TPST) with a Buy and lowers the price target from $11 to $7.
Shares of Tempest Therapeutics Inc (NASDAQ: TPST) are trading sharply higher Wednesday morning as investors respond positively to a strategic agreement expanding the company's next-generation cell therapy pipeline.